{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:37:49Z","timestamp":1761662269328},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1038\/ncponc0174","type":"journal-article","created":{"date-parts":[[2005,5,16]],"date-time":"2005-05-16T09:47:05Z","timestamp":1116236825000},"page":"262-270","source":"Crossref","is-referenced-by-count":26,"title":["Drug Insight: thalidomide as a treatment for multiple myeloma"],"prefix":"10.1038","volume":"2","author":[{"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0174_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","volume":"55","author":"A Jemal","year":"2005","unstructured":"Jemal A et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10\u201330","journal-title":"CA Cancer J Clin"},{"key":"BFncponc0174_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/beha.1999.0015","volume":"12","author":"M Attal","year":"1999","unstructured":"Attal M and Harousseau JL (1999) Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 12: 171\u2013191","journal-title":"Baillieres Best Pract Res Clin Haematol"},{"key":"BFncponc0174_CR3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.11137","volume":"97","author":"KC Anderson","year":"2003","unstructured":"Anderson KC (2003) Moving disease biology from the lab to the clinic. Cancer 97: 796\u2013801","journal-title":"Cancer"},{"key":"BFncponc0174_CR4","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T Hideshima","year":"2000","unstructured":"Hideshima T et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943\u20132950","journal-title":"Blood"},{"key":"BFncponc0174_CR5","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063\u20133067","journal-title":"Blood"},{"key":"BFncponc0174_CR6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","volume":"104","author":"T Hideshima","year":"2004","unstructured":"Hideshima T et al. (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104: 607\u2013618","journal-title":"Blood"},{"key":"BFncponc0174_CR7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.1.5.174","volume":"1","author":"T Hideshima","year":"2002","unstructured":"Hideshima T et al. (2002) The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1: 539\u2013544","journal-title":"Mol Cancer Ther"},{"key":"BFncponc0174_CR8","first-page":"127","volume":"65","author":"K Asosingh","year":"2003","unstructured":"Asosingh K (2003) Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma. Verh K Acad Geneeskd Belg 65: 127\u2013134","journal-title":"Verh K Acad Geneeskd Belg"},{"key":"BFncponc0174_CR9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.V80.9.2306.2306","volume":"80","author":"H Uchiyama","year":"1992","unstructured":"Uchiyama H et al. (1992) Characterization of adhesion molecules on human myeloma cell lines. Blood 80: 2306\u20132314","journal-title":"Blood"},{"key":"BFncponc0174_CR10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","volume":"104","author":"M Abe","year":"2004","unstructured":"Abe M et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell\u2013cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484\u20132491","journal-title":"Blood"},{"key":"BFncponc0174_CR11","doi-asserted-by":"crossref","first-page":"a2354","DOI":"10.1182\/blood-2003-11-3811","volume":"104","author":"S Kumar","year":"2004","unstructured":"Kumar S et al. (2004) Endothelial cells induce multiple myeloma cell proliferation protect against conventional and novel therapies [abstract]. Blood 104: a2354","journal-title":"Blood"},{"key":"BFncponc0174_CR12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","volume":"87","author":"D Chauhan","year":"1996","unstructured":"Chauhan D et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104\u20131112","journal-title":"Blood"},{"key":"BFncponc0174_CR13","first-page":"5850","volume":"63","author":"YT Tai","year":"2003","unstructured":"Tai YT et al. (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3\u2032-kinase\/AKT signaling. Cancer Res 63: 5850\u20135858","journal-title":"Cancer Res"},{"key":"BFncponc0174_CR14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2004-07-2909","volume":"105","author":"K Podar","year":"2005","unstructured":"Podar K and Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105: 1383\u20131395","journal-title":"Blood"},{"key":"BFncponc0174_CR15","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D et al. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950\u20131961","journal-title":"Leukemia"},{"key":"BFncponc0174_CR16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K Podar","year":"2001","unstructured":"Podar K et al. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98: 428\u2013435","journal-title":"Blood"},{"key":"BFncponc0174_CR17","first-page":"2210","volume":"8","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV et al. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8: 2210\u20132216","journal-title":"Clin Cancer Res"},{"key":"BFncponc0174_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.leu.2403285","volume":"18","author":"S Kumar","year":"2004","unstructured":"Kumar S et al. (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18: 624\u2013627","journal-title":"Leukemia"},{"key":"BFncponc0174_CR19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","volume":"104","author":"S Kumar","year":"2004","unstructured":"Kumar S et al. (2004) Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104: 1159\u20131165","journal-title":"Blood"},{"key":"BFncponc0174_CR20","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","volume":"93","author":"JS Damiano","year":"1999","unstructured":"Damiano JS et al. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658\u20131667","journal-title":"Blood"},{"key":"BFncponc0174_CR21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","volume":"32","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32: 290\u2013292","journal-title":"Blood Cells Mol Dis"},{"key":"BFncponc0174_CR22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","volume":"90","author":"M Urashima","year":"1997","unstructured":"Urashima M et al. (1997) The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90: 754\u2013765","journal-title":"Blood"},{"key":"BFncponc0174_CR23","first-page":"6689","volume":"63","author":"CS Mitsiades","year":"2003","unstructured":"Mitsiades CS et al. (2003) Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: biologic and clinical implications. Cancer Res 63: 6689\u20136696","journal-title":"Cancer Res"},{"key":"BFncponc0174_CR24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565\u20131571","journal-title":"N Engl J Med"},{"key":"BFncponc0174_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","volume":"57","author":"T Eriksson","year":"2001","unstructured":"Eriksson T et al. (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57: 365\u2013376","journal-title":"Eur J Clin Pharmacol"},{"key":"BFncponc0174_CR26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/00912700122012698","volume":"41","author":"F Aweeka","year":"2001","unstructured":"Aweeka F et al. (2001) Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. J Clin Pharmacol 41: 1091\u20131097","journal-title":"J Clin Pharmacol"},{"key":"BFncponc0174_CR27","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades N et al. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525\u20134530","journal-title":"Blood"},{"key":"BFncponc0174_CR28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.onc.1201253","volume":"15","author":"D Chauhan","year":"1997","unstructured":"Chauhan D et al. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK\/SAP kinase independent mechanism. Oncogene 15: 837\u2013843","journal-title":"Oncogene"},{"key":"BFncponc0174_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","volume":"17","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch S et al. (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17: 41\u201344","journal-title":"Leukemia"},{"key":"BFncponc0174_CR30","first-page":"53","volume":"25","author":"PA Haslett","year":"1998","unstructured":"Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25: 53\u201357","journal-title":"Semin Oncol"},{"key":"BFncponc0174_CR31","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc R et al. (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787\u20131790","journal-title":"Blood"},{"key":"BFncponc0174_CR32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","volume":"99","author":"SM McHugh","year":"1995","unstructured":"McHugh SM et al. (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99: 160\u2013167","journal-title":"Clin Exp Immunol"},{"key":"BFncponc0174_CR33","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE et al. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210\u2013216","journal-title":"Blood"},{"key":"BFncponc0174_CR34","first-page":"a2213","volume":"96","author":"B Barlogie","year":"2000","unstructured":"Barlogie B et al. (2000) Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM) [abstract]. Blood 96: a2213","journal-title":"Blood"},{"key":"BFncponc0174_CR35","first-page":"a689","volume":"98","author":"B Grosbois","year":"2001","unstructured":"Grosbois B et al. (2001) Thalidomide (Thal) in the Treatment of advanced multiple myeloma (MM). A prospective study of 120 patients [abstract]. Blood 98: a689","journal-title":"Blood"},{"key":"BFncponc0174_CR36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4065\/78.1.34","volume":"78","author":"S Kumar","year":"2003","unstructured":"Kumar S et al. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34\u201339","journal-title":"Mayo Clin Proc"},{"key":"BFncponc0174_CR37","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2004.10.052","volume":"22","author":"SA Schey","year":"2004","unstructured":"Schey SA et al. (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22: 3269\u20133276","journal-title":"J Clin Oncol"},{"key":"BFncponc0174_CR38","first-page":"a3531","volume":"98","author":"G Tricot","year":"2001","unstructured":"Tricot G et al. (2001) Angiochemotherapy (ACT) for multiple myeloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control [abstract]. Blood 98: a3531","journal-title":"Blood"},{"key":"BFncponc0174_CR39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D et al. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16\u201319","journal-title":"J Clin Oncol"},{"key":"BFncponc0174_CR40","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV et al. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20: 4319\u20134323","journal-title":"J Clin Oncol"},{"key":"BFncponc0174_CR41","doi-asserted-by":"crossref","first-page":"a205","DOI":"10.1182\/blood.V104.11.205.205","volume":"104","author":"SV Rajkumar","year":"2004","unstructured":"Rajkumar SV et al. (2004) Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 104: a205","journal-title":"Blood"},{"key":"BFncponc0174_CR42","doi-asserted-by":"crossref","first-page":"a335","DOI":"10.1182\/blood-2004-01-0200","volume":"104","author":"KA Stewart","year":"2004","unstructured":"Stewart KA et al. (2004) Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant [abstract]. Blood 104: a335","journal-title":"Blood"},{"key":"BFncponc0174_CR43","doi-asserted-by":"crossref","first-page":"a535","DOI":"10.1182\/blood-2004-01-0169","volume":"104","author":"M Attal","year":"2004","unstructured":"Attal M et al. (2004) Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02) [abstract]. Blood 104: a535","journal-title":"Blood"},{"key":"BFncponc0174_CR44","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdf188","volume":"13","author":"R Alexanian","year":"2003","unstructured":"Alexanian R et al. (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Ann Oncol 13: 1116\u20131119","journal-title":"Ann Oncol"},{"key":"BFncponc0174_CR45","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","volume":"93","author":"IE Fahdi","year":"2004","unstructured":"Fahdi IE et al. (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93: 1052\u20131055","journal-title":"Am J Cardiol"},{"key":"BFncponc0174_CR46","first-page":"408","volume":"87","author":"P Tosi","year":"2002","unstructured":"Tosi P et al. (2002) Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma. Haematologica 87: 408\u2013414","journal-title":"Haematologica"},{"key":"BFncponc0174_CR47","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0145-2126(03)00027-4","volume":"27","author":"SA Schey","year":"2003","unstructured":"Schey SA et al. (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 27: 909\u2013914","journal-title":"Leuk Res"},{"key":"BFncponc0174_CR48","first-page":"404","volume":"86","author":"M Hus","year":"2001","unstructured":"Hus M et al. (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86: 404\u2013408","journal-title":"Haematologica"},{"key":"BFncponc0174_CR49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/sonc.2002.34075","volume":"29","author":"BG Durie","year":"2002","unstructured":"Durie BG (2002) Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 29: 34\u201338","journal-title":"Semin Oncol"},{"key":"BFncponc0174_CR50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","volume":"17","author":"SV Rajkumar","year":"2003","unstructured":"Rajkumar SV et al. (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17: 775\u2013779","journal-title":"Leukemia"},{"key":"BFncponc0174_CR51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","volume":"109","author":"G Juliusson","year":"2000","unstructured":"Juliusson G et al. (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109: 89\u201396","journal-title":"Br J Haematol"},{"key":"BFncponc0174_CR52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","volume":"18","author":"R Garcia-Sanz","year":"2004","unstructured":"Garcia-Sanz R et al. (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma. Leukemia 18: 856\u2013863","journal-title":"Leukemia"},{"key":"BFncponc0174_CR53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","volume":"122","author":"MH Kropff","year":"2003","unstructured":"Kropff MH et al. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122: 607\u2013616","journal-title":"Br J Haematol"},{"key":"BFncponc0174_CR54","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/sj.thj.6200401","volume":"5","author":"M Offidani","year":"2004","unstructured":"Offidani M et al. (2004) Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 5: 312\u2013317","journal-title":"Hematol J"},{"key":"BFncponc0174_CR55","doi-asserted-by":"crossref","first-page":"a1482","DOI":"10.1182\/blood-2004-01-0342","volume":"104","author":"MA Dimopoulos","year":"2004","unstructured":"Dimopoulos MA et al. (2004) Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma \u2265 75 years of age [abstract]. Blood 104: a1482","journal-title":"Blood"},{"key":"BFncponc0174_CR56","doi-asserted-by":"crossref","first-page":"a207","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A et al. (2004) A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis [abstract]. Blood 104: a207","journal-title":"Blood"},{"key":"BFncponc0174_CR57","doi-asserted-by":"crossref","first-page":"a1480","DOI":"10.1182\/blood.V104.11.1480.1480","volume":"104","author":"M Zangari","year":"2004","unstructured":"Zangari M et al. (2004) Marked activity of velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]. Blood 104: a1480","journal-title":"Blood"},{"key":"BFncponc0174_CR58","doi-asserted-by":"crossref","first-page":"a210","DOI":"10.1182\/blood.V104.11.210.210","volume":"104","author":"R Alexanian","year":"2004","unstructured":"Alexanian R et al. (2004) VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood 104: a210","journal-title":"Blood"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0174","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:37:59Z","timestamp":1684442279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["BFncponc0174"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0174","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}